Core Viewpoint - The term "DeepSeek moment" is emerging as a topic in global stock markets, symbolizing the disruption of global industry structures and mainstream technologies by innovations originating from China, particularly in the AI and biopharmaceutical sectors [1][3]. Group 1: AI Industry - In January, the Chinese emerging enterprise DeepSeek launched a low-cost generative AI, challenging the United States' dominance in the AI sector [1]. - The "DeepSeek moment" reflects a significant shift in technological leadership from the U.S. to China, indicating a potential change in global power dynamics [1]. Group 2: Biopharmaceutical Industry - Following the AI sector, the biopharmaceutical industry is experiencing its own "DeepSeek moment," highlighted by Pfizer's exclusive licensing agreement with China's 3SBio for cancer treatment drug development and production [3]. - After the announcement, 3SBio's stock surged by 70% compared to the end of April, showcasing investor confidence in Chinese biopharmaceutical companies [3]. - Since the end of 2024, the stock index of biotechnology companies listed in Hong Kong has increased by 51%, significantly outperforming the Hang Seng Index (17%) and the S&P 500 Index (1%), indicating high investor expectations for Chinese biotech firms [3].